Savanna Biotherpeutics
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
Savanna Biotherapeutics is pioneering the world's first iPSC-derived microglia cell therapy platform. Our lead program, SB-101, replaces dysfunctional microglia in patients with ALSP, a fatal neurodegenerative disease caused by CSF1R mutations with no approved treatments. Delivered via a one-time procedure, SB-101 microglia engraft, self-renew, and migrate throughout the brain — a living therapeutic providing durable, CNS-wide disease modification. Backed by five landmark publications and founded by world-leading glial biologists, Savanna has achieved FDA alignment and is advancing toward IND filing and first-in-human dosing. Beyond ALSP, our platform unlocks a pipeline across microgliopathies and broader neurodegeneration where engineered microglia serve as cellular vehicles for CNS-wide delivery of therapeutic proteins. Savanna is at a rare inflection point: de-risked science, clear regulatory path, and first-mover advantage in an entirely new therapeutic modality for the brain.
Company HQ City:
Aliso Viejo
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2021
Lead Product in Development:
Our lead program, SB-101, replaces dysfunctional microglia in patients with ALSP, a fatal neurodegenerative disease caused by CSF1R mutations with no approved treatments. Delivered via a one-time MRI-guided stereotactic procedure, SB-101 microglia engraft, self-renew, and migrate throughout the brain — a living therapeutic providing durable, CNS-wide disease modification.
CEO
Robert Spitale
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
IND - 1H 2027
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}